Research location
Miyagi
Japan
Advertisement
Research activity in Miyagi
JapanCureCurrent currently publishes aggregate city-level research activity for this location: 131 trials and 185 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Miyagi
131 linked trials · page 1 of 3Futibatinib (TAS-120) in Patients With Advanced Biliary Tract CancerNCT07710885 · 2026-06-24 · 1 site observation
RECRUITING
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerNCT06793215 · 2025-10-24 · 1 site observation
RECRUITING
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]NCT07099898 · 2025-08-11 · 1 site observation
RECRUITING
A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease DementiaNCT06803823 · 2025-05-01 · 1 site observation
RECRUITING
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerNCT06801834 · 2025-04-04 · 1 site observation
RECRUITING
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung CancerNCT06712355 · 2025-02-03 · 1 site observation
RECRUITING
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsNCT05899608 · 2023-10-26 · 1 site observation
RECRUITING
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung CancerNCT06497556 · 2024-09-23 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)NCT06472076 · 2024-06-10 · 1 site observation
ACTIVE_NOT_RECRUITING
Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled AsthmaNCT06372496 · 2024-04-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEINCT05826366 · 2023-06-02 · 1 site observation
COMPLETED
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationNCT05636176 · 2023-05-08 · 3 site observations
TERMINATED
TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)NCT05729711 · 2023-04-04 · 1 site observation
ACTIVE_NOT_RECRUITING
LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)NCT05677308 · 2023-03-07 · 1 site observation
COMPLETED
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)NCT05555732 · 2023-01-11 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary DiseaseNCT05595642 · 2022-12-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung CancerNCT05502237 · 2022-10-12 · 1 site observation
ACTIVE_NOT_RECRUITING
A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular HypertensionNCT05495061 · 2022-08-09 · 1 site observation
COMPLETED
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTENCT05171049 · 2022-05-05 · 1 site observation
TERMINATED
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT05089734 · 2021-11-17 · 1 site observation
ACTIVE_NOT_RECRUITING
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLCNCT04919811 · 2021-09-01 · 1 site observation
ACTIVE_NOT_RECRUITING
Forxiga HF General Drug Use-Results StudyNCT04865406 · 2021-05-10 · 1 site observation
COMPLETED
IMFINZI Study in Patients With Extensive Stage Small Cell Lung CancerNCT04854590 · 2021-04-22 · 1 site observation
COMPLETED
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic PhenotypeNCT04718389 · 2021-01-26 · 1 site observation
COMPLETED
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung CancerNCT04619797 · 2020-12-15 · 1 site observation
COMPLETED
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and ChemotherapyNCT04655976 · 2020-12-08 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin BeforeNCT04460885 · 2020-11-25 · 1 site observation
COMPLETED
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)NCT04546009 · 2020-10-09 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing ChemotherapyNCT04471428 · 2020-10-01 · 1 site observation
COMPLETED
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)NCT04513925 · 2020-08-24 · 1 site observation
COMPLETED
Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®NCT04469855 · 2020-07-27 · 4 site observations
COMPLETED
Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)NCT04333147 · 2020-05-12 · 2 site observations
TERMINATED
Study To Assess Frequency Of Serious Infections In Clinical Practice In Japan For Adult Participants With Rheumatoid Arthritis Receiving Oral RINVOQ TabletsNCT04340115 · 2020-04-24 · 1 site observation
COMPLETED
A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung CancerNCT04294810 · 2020-03-04 · 1 site observation
COMPLETED
Mid-Q Response StudyNCT04180696 · 2020-01-23 · 1 site observation
COMPLETED
Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) InhibitorsNCT04134728 · 2019-10-31 · 1 site observation
COMPLETED
Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid ArthritisNCT03971253 · 2019-09-02 · 1 site observation
COMPLETED
A Heart Disease Study of Semaglutide in Patients With Type 2 DiabetesNCT03914326 · 2019-06-17 · 1 site observation
COMPLETED
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)NCT03970837 · 2019-06-05 · 2 site observations
TERMINATED
Radiation Therapy (HB-001) by Alpha-particle Sources for Recurrent Malignant Solid Tumors in JapanNCT04906070 · 2019-05-25 · 1 site observation
COMPLETED
A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast CancerNCT03726879 · 2019-01-11 · 1 site observation
COMPLETED
IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation TherapyNCT03643484 · 2018-10-24 · 1 site observation
COMPLETED
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or ObesityNCT03574597 · 2018-10-24 · 1 site observation
COMPLETED
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung CancerNCT03456076 · 2018-08-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Lynparza Breast Cancer Clinical Experience InvestigationNCT03590938 · 2018-08-14 · 1 site observation
COMPLETED
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast CancerNCT03498716 · 2018-08-02 · 1 site observation
TERMINATED
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]NCT03523585 · 2018-08-01 · 1 site observation
COMPLETED
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast CancerNCT03493854 · 2018-06-14 · 1 site observation
COMPLETED
FASENRA SCEI for Long-term UseNCT03588546 · 2018-05-31 · 1 site observation
COMPLETED
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)NCT03456063 · 2018-04-24 · 2 site observations
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.